Vestal Point Capital LP Makes New Investment in enGene Holdings Inc. (NASDAQ:ENGN)

Vestal Point Capital LP purchased a new position in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 370,000 shares of the company's stock, valued at approximately $2,460,000. Vestal Point Capital LP owned 0.84% of enGene as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in enGene in the fourth quarter worth $6,120,000. Vontobel Holding Ltd. bought a new position in shares of enGene during the fourth quarter valued at $69,000. Sphera Funds Management LTD. bought a new position in shares of enGene during the fourth quarter valued at $3,724,000. Fcpm Iii Services B.V. increased its holdings in shares of enGene by 11.0% during the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock valued at $64,057,000 after acquiring an additional 954,610 shares in the last quarter. Finally, Corton Capital Inc. bought a new position in shares of enGene during the fourth quarter valued at $157,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ENGN shares. Morgan Stanley reduced their price target on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. UBS Group downgraded enGene from a "buy" rating to a "neutral" rating and reduced their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a report on Tuesday, April 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $23.29.

enGene Stock Performance

NASDAQ:ENGN traded down $0.05 on Friday, hitting $4.24. The stock had a trading volume of 45,475 shares, compared to its average volume of 132,554. The stock has a market cap of $216.15 million, a price-to-earnings ratio of -7.31 and a beta of -0.36. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The business's 50-day simple moving average is $4.07 and its two-hundred day simple moving average is $5.94. enGene Holdings Inc. has a 52-week low of $2.65 and a 52-week high of $13.00.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.